

# CURRICULUM VITAE

## PERSONAL DATA

---

**Name** **JERRY L. BAUMAN, Pharm.D., FCCP, FACC**

**Business Address** University of Illinois at Chicago  
College of Pharmacy, M/C 886  
833 South Wood Street  
Chicago, Illinois 60612  
(312) 996-3267 or 6300  
FAX: (312) 996-0379  
Email: jbauman@uic.edu

---

## CURRENT POSITION

---

**Dean, College of Pharmacy**  
**Professor**, Departments of Pharmacy Practice and  
Medicine, Section of Cardiology (RT)  
University of Illinois at Chicago  
Chicago, Illinois

---

## CERTIFICATION & LICENSURE

---

**Licensure** Illinois Registered Pharmacist (active)  
#51-30897

**Board Certification** Pharmacotherapy Specialist  
with Added Qualifications in  
Cardiology #2-93-389  
1994-2008

---

## EDUCATION, TRAINING AND PAST POSITIONS

---

**Bachelor of Science in Pharmacy, 1976**  
Graduation with Honors (Rho Chi, Phi Kappa Phi)  
University of Illinois at the Medical Center  
Chicago, Illinois

**Doctor of Pharmacy, 1978**  
University of Missouri-Kansas City  
Kansas City, Missouri

**Hospital Pharmacy Resident, 1977**  
University of Illinois Hospital  
Chicago, Illinois

**Clinical Pharmacy Resident, 1979**

Instructor in Medicine and Clinical Pharmacy  
Department of Medicine, Section of Clinical Pharmacology  
University of Missouri at Kansas City  
Truman Medical Center  
Kansas City, Missouri

**CIC Fellowship in Academic Administration 1991**

University of Illinois at Chicago  
Chicago, Illinois

**University of Illinois at Chicago, Colleges of Pharmacy and Medicine 1979 - present**

**Assistant Professor** of Pharmacy Practice, 1979-1984  
Departments of Pharmacy Practice and Medicine, Section of Cardiology

**Associate Professor** of Pharmacy Practice, 1984-1994  
Departments of Pharmacy Practice and Medicine, Section of Cardiology

**Assistant Head for Research**, 1984-1998  
Department of Pharmacy Practice

**Chief**, Section of Cardiovascular Pharmacotherapy, 1984-1998  
Department of Pharmacy Practice

**Professor of Pharmacy Practice**, 1994-present  
Departments of Pharmacy Practice and Medicine, Section of Cardiology

**Head**, Department of Pharmacy Practice, 1998-2007

**Interim Vice Chancellor for Academic Affairs and Provost**, 2011

**Dean**, College of Pharmacy, 2007-present

---

**AWARDS**

---

William Au Lecturer, SUNY-Syracuse Department of Medicine, 2003

Who's Who in America – 2002, 2009, 2010, 2011

UIC College of Pharmacy - Dean's Award for contributions to the profession - 2001

Howard Ferguson Lecturer, University of North Carolina - 2000

Robert G. Leonard Memorial Lecturer, University of Texas - 1999

Distinguished Member (elected), National Academy of Practitioners (inaugural pharmacy group)  
– 1997

Russell R. Miller Award for Research Contributions, American College of Clinical Pharmacy –  
1994

Fellow (elected), American College of Cardiology (first PharmD) - 1993  
Fellow (elected), American College of Clinical Pharmacy - 1991  
American Heart Association of Metropolitan Chicago Gold Award for Research - 1991  
University of Illinois College of Pharmacy Alumni Loyalty Award - 1989  
Outstanding Teacher of the Year Award - 1988  
Special Recognition Award, post-B.S., PharmD program - 1986  
Golden Apple Award for best instructor PharmD program - 1984  
Outstanding Teacher of the Year Award - PharmD program - 1984  
Golden Apple Award for best instructor PharmD program - 1983  
Lilly Achievement Award for Scholarship, Ethics, and Leadership - 1976  
Frank Lieberman Award for Pharmacy Administration - 1976

---

**SELECT FELLOWS, RESIDENTS AND STUDENTS MENTORED**

---

Research Fellows and Specialized Residents in Cardiovascular Pharmacotherapy

1985-6	Steven I. Berk, PharmD, MD, Associate Professor of Clinical Medicine, Albert Einstein College of Medicine
1987-9	Robert B. Parker, PharmD, FCCP, Professor of Clinical Pharmacy, University of Tennessee
1987-9	Patrick McCollam, PharmD, Senior Research Associate, Health Outcomes, Eli Lilly Company
1988-9	Marieke D. Schoen, PharmD, Clinical Associate Professor and Associate Dean for Academic Affairs, University of Illinois at Chicago College of Pharmacy
1992-3	Harumi Takahashi, PhD, Associate Professor, Meiji College of Pharmacy, Tokyo (visiting scholar)
1993-5	Bradley G. Phillips, PharmD, FCCP, Millikin Reeve Professor of Clinical Pharmacy and Head, Department of Clinical and Administrative Pharmacy, University of Georgia
1994-6	Ashesh J. Ghandi, PharmD, Associate Director, Global Medical Affairs, Wyeth Pharmaceuticals
1996-7	Mary Ross Southworth, PharmD, Deputy Director, Office of New Drugs Division of Cardiovascular and Renal, Food and Drug Administration
1996-8	Cynthia A. Sanoski, PharmD, FCCP, Professor and Head, Department of Pharmacy Practice, Thomas Jefferson University
1997-9	Robert J. DiDomenico, PharmD, Clinical Associate Professor, Departments Pharmacy Practice and Medicine, Section of Cardiology, University of Illinois at Chicago

General Residents and Students

1979-80	Michael S. Maddux, PharmD, FCCP, Executive Director, American College of Clinical Pharmacy
1983-4	Mark Munger, PharmD, FCCP, FACC, Professor and Associate Dean, University of Utah College of Pharmacy

1987-9 Eric Stanek, PharmD, FCCP, Senior Director, Research,  
Personalized Medicine, Medco Health Solutions  
1997-8 Donna Leslie, PharmD, VISN 12 Pharmacist Executive, Veterans  
Administration

---

## ORIGINAL PUBLICATIONS

---

1. Bauman JL, Siepler JK, Fitzloff J: Phenytoin Crystallization in Intravenous Fluids. *Drug Intelligence and Clinical Pharmacy* 11:646-649, 1977.
2. Elenbaas RM, Payne VW, Bauman JL: Influence of Clinical Pharmacist Consultations on the Use of Drug Blood Level Tests. *American Journal of Hospital Pharmacy* 37:61-64, 1980.
3. Kelly KL, Covinsky JO, Fendler K, Bauman JL: The Impact of Clinical Pharmacist's Activity on Intravenous Fluid and Medication Administration. *Drug Intelligence and Clinical Pharmacy* 14:516-520, 1980.
4. Bauman JL, Elenbaas J, Hamburger SC: Cimetidine - A Review. *Journal of the American Medical Women Association* 37:61-64, 1980.
5. Bauman JL, Curtis RA: Diuretics in Hypertension. *Therapeutics* 8:1-8, 1980.
6. Lee M, Fondriest-Gentry A, Schwartz R, Bauman JL: Tartrazine Containing Drugs. *Drug Intelligence and Clinical Pharmacy* 15:782-788, 1981.
7. Bauman JL, Shulruff S, Hasegawa GR, Roden R, Hartsough N, Bauernfeind RA: Fever due to Hydroxyurea. *Archives of Internal Medicine* 141:260-261, 1981.
8. Maddux MS, Leeds NH, Organek HW, Hasegawa GR, Bauman JL: Erythromycin Alteration of Theophylline Pharmacokinetics: Lack of Effect at Steady State. *Chest* 81:563-565, 1982.
9. Giacona N, Bauman JL, Siepler JK: Crystallization of Three Phenytoin Preparations in Intravenous Fluids. *American Journal of Hospital Pharmacy* 39:630-634, 1982.
10. Bauman JL: Understanding and Treating Supraventricular Arrhythmias. *Clinical Pharmacy* 2:312-320, 1983.
11. Brown DL, Maddux M, Organek HW, Bauman JL: Rapid and Sustained Oral Theophylline Loading: An Alternative to Intravenous Aminophylline. *Archives of Internal Medicine* 143:794-796, 1983.
12. Strasberg B, Prechel D, Bauman JL, Coelho A, Swiryn S, Bauernfeind R, Rosen KM: Long-term Follow-up of Patients on Aprindine: Safety and Efficacy. *Archives Internal*

- Medicine* 143:2131-2133, 1983.
13. Bauman JL, Bauernfeind RA, Hoff JV, Strasberg B, Swiryn S, Rosen KM: Torsade de Pointes due to Quinidine: Observations in 31 Patients. *American Heart Journal* 107:425-430, 1984.
  14. Curtis RA, Giacona N, Burrows D, Bauman JL, Schaffer, M: Fatal Maprotiline Intoxication. *Drug Intelligence and Clinical Pharmacy* 18:716-720, 1984.
  15. Bauman JL, Gallastegui J: Quinidine Syncope due to Torsade de Pointes. *Cardiology Board Review* 1:54-64, 1985.
  16. Bauman JL, Gallastegui J, Strasberg B, Swiryn S, Hoff JV, Welch W, Bauernfeind RA: Long-term Therapy with Disopyramide Phosphate: Side Effects and Effectiveness. *American Heart Journal* 111:654-660, 1986.
  17. Schrader B, Bauman JL: Mexiletine: A New Type I Antiarrhythmic Drug. *Drug Intelligence and Clinical Pharmacy* 20:255-260, 1986.
  18. Bauman JL, et al: Cardiac Arrhythmias *Illinois Pharmacist*  
Part 1. Mechanisms of Cardiac Arrhythmias and the Antiarrhythmic Agents. April 1986 pp 25-28.  
Part 2. Atrial Fibrillation and Flutter. May 1986 pp 23-26.  
Part 3. Torsade de Pointes: Characteristics, Causes and Treatment. June 1986 pp 15-20.  
Part 4. Paroxysmal Supraventricular Tachycardia due to Reentry. July 1986 pp 23-33.  
Part 5. Ventricular Arrhythmias. January, 1987 pp 11-32.
  19. Schrader BJ, Bauman JL, Zeller FP, Shanes JG, Rich S: Acceptance of Transcutaneous Nitroglycerin Patches by Patients with Angina Pectoris. *Pharmacotherapy* 6:83-86, 1986.
  20. Bauman JL, Gallastegui J: Dilemmas in Drug Usage: Quinidine Induced Torsade de Pointes. *Hospital Therapy* 11:45-50, 1986.
  21. Kasuya A, Bauman JL, Curtis RA, Duarte B, Hutchinson RA: Clinical Pharmacy On-call Program in an Emergency Room: Description and Evaluation. *American Journal of Emergency Medicine* 4:464-467, 1986.
  22. Bauman JL, Gallastegui J, Prechel D, Anderson JL: Bethanedine Sulfate in Paroxysmal Ventricular Tachycardia. A Study Using Programmed Cardiac Stimulation. *Pharmacotherapy* 6:184-192, 1986.
  23. Hoon T, Bauman JL, Rodvold K, Gallastegui J, Hariman RJ: The Pharmacokinetic and Pharmacodynamic Differences of the d- and l- Isomers of Verapamil: Implications in the Treatment of PSVT. *American Heart Journal* 112:396-403, 1986.
  24. Barbarash RA, Bauman JL, Lukazewski, AA, Srebro JP, Rich S: Verapamil infusions in the Treatment of Atrial Tachyarrhythmias. *Critical Care Medicine* 14:886-888, 1986.

25. Berk SI, Anders R, Bauman JL: The Newly Approved Antiarrhythmic Drugs: Mexiletine, Tocainide, Flecainide and Amiodarone. *Hospital Physician* 22:28-48, 1986.
26. Miller SM, Martinez JJ, Deal BJ, Bauman JL, Scagliotti D, Hariman RJ, Gallastegui JL: Electrophysiologic Testing of Tocainide and Mexiletine for Ventricular Tachycardia: Assessment of the Need to Test Both Drugs. *American Heart Journal* 112:1114-1116, 1986.
27. Berk SI, Gal P, Bauman JL, Douglas JB, McCue JD, Powell JR: The Effect of Oral Cimetidine on Total and Unbound Serum Lidocaine Concentrations in Patients with Suspected Myocardial Infarction. *International Journal of Cardiology* 14:91-94, 1987.
28. Bauman JL, Gallastegui J, Tanenbaum SR, Hariman RJ: Flecainide Induced Sustained Ventricular Tachycardia Successfully Treated with Lidocaine. *Chest* 92:573-575, 1987.
29. Bauman JL, Berk SI, Hariman RJ, Langenberg PW, Deal BJ, Beckman K, Brownstein S, Gallastegui JL: Amiodarone for Sustained Ventricular Tachycardia: Efficacy, Safety and Factors Influencing Long-Term Outcome. *American Heart Journal* 114:1436-1444, 1987.
30. Berry NS, Bauman JL, Gallastegui JL, Bauma W, Beckman KJ, Hariman RJ: Analysis of Antiarrhythmic Drug Concentrations During Electrophysiologic Drug Testing in Patients with Inducible Tachycardias. *American Journal of Cardiology* 61:922-924, 1988.
31. Gallastegui JL, Bauman JL, Anderson JL, Winkle RA, Ezri MD, Westveer DC, Swiryn S: Worsening of Ventricular Tachycardia by Amiodarone. *Journal of Clinical Pharmacology* 28:406-411, 1988.
32. Shanes JG, Wolfkiel C, Ghali J, Dierenfeldt BJ, Kondos GT, Bauman JL: Acute Hemodynamic Effects of Pindolol and Propranolol in Patients with Dilated Cardiomyopathy: Relevance of Intrinsic Sympathomimetic Activity. *American Heart Journal* 116:1268-1275, 1988.
33. Dekker-Schoen M, Bauman JL: The Use of Continuous Infusion Verapamil. *Clinical Pharmacy* 7:791, 1988.
34. Barbarash RA, Bauman JL, Fischer JH, Kondos GT, Batenhorst RL: Near Total Reduction in Verapamil Bioavailability by Rifampin: Electrocardiographic Correlates. *Chest* 94:954-959, 1988.
35. Parker R, McCollam PL, Bauman JL: Propafenone: A Novel Type Ic Antiarrhythmic Drug. *Annals of Pharmacotherapy* 23:196-202, 1989.
36. Hariman RJ, Beckman KJ, Gomes JAC, Bauman JL, El-Sherif N: Cryothermal Mapping of the Sinus Node in Dogs. A Simple Method of Localizing Dominant and Latent Pacemakers. *Cardiovascular Research* 23:231-238, 1989.
37. McCollam PL, Bauman JL, Beckman KJ, Hariman RI: A Simple Method of Monitoring Antiarrhythmic Drugs During Short and Long-term Therapy. *American Journal of Cardiology* 63:1273-1275, 1989.

38. Bauman JL: The Results of the CAST.... What Did We Catch? *Pharmacotherapy* 9:267-268, 1989.
39. McCollam PL, Parker R, Bauman JL, Beckman K, Hariman R: Proarrhythmia: A Paradoxical Response to Antiarrhythmic Drugs. *Pharmacotherapy* 9:144-153, 1989.
40. Majerus TC, Dasta JF, Bauman JL, Danziger LH, Ruffolo RR: Dobutamine: Ten Years Later. *Pharmacotherapy* 9:245-259, 1989.
41. McCollam PL, Bauman JL: New Concepts in Antiarrhythmic Drug Monitoring. *Journal of Pharmacy Practice* 2:393-402, 1989.
42. Beckman KJ, Gallastegui JL, Bauman JL, Hariman RJ: The Predictive Value of Electrophysiologic Studies in Untreated Patients with the Wolff-Parkinson-White Syndrome. *Journal of the American College of Cardiology* 15:640-647, 1990.
43. Hariman RJ, Hu D, Gallastegui JL, Beckman KJ, Bauman JL: High Incidence of Remission in Patients with Incessant Ventricular Tachycardia Discontinued from Antiarrhythmic Drugs. *American Journal of Cardiology* 66:831-836, 1990.
44. Stanek EJ, Schoen MD, Bauman JL: Issues in the Treatment of Ventricular Ectopy: Controversy Past, Present and Future. *Journal of Pharmacy Practice* 3:283-294, 1990.
45. Bauman JL. Antiarrhythmics, drug concentrations and generic substitution. *Clinical Dialogues on Arrhythmias* 2:1-4, 1990.
46. Beckman KJ, Bauman JL, Pimental PA, Garrard C, Hariman RJ: Arsenic Induced Torsade de Pointes. *Critical Care Medicine* 19:290-292, 1991.
47. Bauman JL, Schoen MD, Hoon TJ: Practical Optimization of Antiarrhythmic Drug Therapy Utilizing Pharmacokinetic Principles. *Clinical Pharmacokinetics* 20:151-166, 1991.
48. Schoen MD, Parker RB, Hoon TJ, Hariman RJ, Bauman JL, Beckman KJ: Evaluation of the Pharmacokinetics and Electrocardiographic Effects of IV Verapamil with IV Calcium Chloride Pretreatment. *American Journal of Cardiology* 67:300-304, 1991.
49. Just VL, Schrader BJ, Paloucek FP, Hoon TJ, Leikin JB, Bauman JL: Evaluation of Drug Therapy for the Treatment of Hypertensive Urgencies in the Emergency Department. *American Journal of Emergency Medicine* 9:107-111, 1991.
50. Beckman KJ, Parker RB, Hariman RJ, Gallastegui JL, Javaid JI, Bauman JL: The Hemodynamic and Electrophysiologic Actions of Cocaine: Effect of Sodium Bicarbonate as an Antidote. *Circulation* 83:1799-1809, 1991.
51. Schrader BJ, Maddux MS, Veremis SA, Moses MR, Maturen A, Bauman JL: Digitalis-Like-Immunoreactive Substance in Renal Transplant Recipients. *Journal of Clinical*

- Pharmacology* 31:1126-1131, 1991.
52. Berk SI, Beckman KJ, Hoon TJ, Hariman RJ, Siegal FP, Hu D, Bauman JL: A Comparison of the Pharmacokinetics and Electrocardiographic Effects of Sublingual and Intravenous Verapamil. *Pharmacotherapy* 12:33-39, 1992.
  53. Tworek DA, Nazari J, Ezri MD, Bauman JL: Antiarrhythmic Agents and Their Influence on Pacemakers: A Drug-Device Interaction. *Clinical Pharmacy* 11:48-56, 1992.
  54. Berry NS, Folstad JE, Bauman JL, Leikin JB: Follow-up Observations on 24 Hour Pharmacotherapy Services in the Emergency Department. *Annals of Pharmacotherapy* 26:476-480, 1992.
  55. Hoon TJ, McCollam PL, Beckman KJ, Hariman RJ, Bauman JL: The Impact of Food on the Pharmacokinetics and Electrocardiographic Effects of Sustained Release Verapamil in Normal Subjects. *American Journal of Cardiology* 70:1072-1076, 1992.
  56. Nazari J, Bauman JL, Pham T, Ivanovich L, Kehoe RF: Exercise-Induced Fatal Sinusoidal Ventricular Tachycardia Secondary to Moricizine. *Pacing and Clinical Electrophysiology* 15:1421-1424, 1993.
  57. Roberts SA, Diaz C, Nolan PE, Salerno DM, Stapczynski JS, Zbrozek AS, Ritz EG, Bauman JL, Vlasses PH. Effectiveness and Costs of Digoxin Treatment for Atrial Fibrillation and Flutter. *American Journal of Cardiology* 72:567-573, 1993.
  58. LaBreche DG, Kondos GT, Bartels DW, Vallejo-Sinavsky VL, Bauman JL. Variability in Plasma Lipoprotein Profiles When Comparing Diltiazem and Propranolol. *Annals of Pharmacotherapy* 27:1048-1052, 1993.
  59. Bauman JL: Strategies in the Formulary Management of Cardiovascular Drugs. *P & T Journal* 18:12-13, 1993.
  60. Piscitelli DA, Fischer J, Schoen MDS, Hoon TJ, Bauman JL. Bioavailability of Total and Unbound Disopyramide: Implications for Clinical Use of the Immediate and Controlled - Release Dosage Forms. *Journal of Clinical Pharmacology* 34:823-828, 1994.
  61. Phillips BG, Bauman JL. Arrhythmias 1994 - Key References. *Hospital Pharmacy* 29:954-955, 1994.
  62. Oberg KC, O'Toole MF, Gallastegui JL, Bauman JL. Observations in Patients with "Late" Proarrhythmia Due to Quinidine. *American Journal of Cardiology* 74:192-194, 1994.
  63. Bauman JL, Winecoff AP, Grawe JJ, Hariman RJ. Sudden Death Due to Cocaine: A Hypothesis Incorporating Basic and Clinical Science. *Journal of Clinical Pharmacology* 34:902-911, 1994.
  64. Roberts SA, Viana M, Nazari J, Bauman JL. Invasive and Noninvasive Methods to Determine the Effectiveness of Amiodarone in Sustained Ventricular Tachycardia. A

Compilation of Clinical Observations Using Meta-Analysis. *Pacing and Clinical Electrophysiology* 17:1590-1602, 1994

65. Winecoff AP, Hariman RJ, Grawe JJ, Wang JJ, Bauman JL. Reversal of the Electrocardiographic Effects of Cocaine by Lidocaine Part 1. Comparison with Sodium Bicarbonate and Quinidine. *Pharmacotherapy* 14:698-703, 1994.
66. Grawe JJ, Hariman RJ, Winecoff AP, Fischer JH, Bauman JL. Reversal of the Electrocardiographic Effects of Cocaine by Lidocaine Part 2. Concentration-Effect Relationships. *Pharmacotherapy* 14:704-711, 1994.
67. Bauman JL: Drug Safety: Cardiac Arrhythmias. Proceedings of the Antihistamine Consensus Conference. *Hospital Medicine* (Suppl) 31:23-25, 1994
68. Bell D, Thoele DG, Gurpreet M, Bauman JL. Effective Use of Intravenous Magnesium for Acquired Torsade de Pointes in a 4 Month-Old Infant. *Pediatric Cardiology* 16:79-81, 1995.
69. Phillips BG, Bauman JL. Prescribing Trends and Pharmacoeconomic Considerations of Antiarrhythmic Drugs: A Focus on Atrial Fibrillation and Flutter. *PharmacoEconomics* 7: 521-533, 1995.
70. Yim JM, Brown EJ, Bauman JL, Bittar N, Celestin C, Hoon TJ, Phillips BG, Vlasses PH. Angiotensin Converting Enzyme Inhibitor Use in Survivors of Acute Myocardial Infarction *American Journal of Cardiology* 75:1184-1186, 1995.
71. Oberg KC, Bauman JL. QT Prolongation and Torsade de Pointes Due to Erythromycin Lactobionate. *Pharmacotherapy* 15:687-692,1995.
72. Phillips BG, Yim JM, Brown EJ, Bittar N, Hoon TJ, Celestin C, Vlasses PH, Bauman JL. A Pharmacologic Profile of Survivors of Acute Myocardial Infarction at United States Academic Hospitals. *American Heart Journal* 131:872-878, 1996.
73. Liu D, Hariman RJ, Bauman JL. Cocaine Concentration-Effect Relationship in the Presence and Absence of Lidocaine: Evidence of Competitive Binding Between Cocaine and Lidocaine. *Journal of Pharmacology and Experimental Therapeutics* 276:568-577, 1996.
74. Phillips BG, Bauman JL, Schoen MDS, Hoon TJ, Schrader BJ, Rich S. Serum Nifedipine Concentrations and Response of Patients with Pulmonary Hypertension. *American Journal of Cardiology* 77:996-999, 1996.
75. Evans RR, Phillips BG, Singh G, Bauman JL, Gulati A. Endothelin-1: Racial and Gender Differences in Healthy Volunteers. *American Journal of Cardiology* 78:486-488, 1996.
76. Bauman JL: Drug Interactions: Antiarrhythmic Agents. *Cardiology* 3:49-52, 1996.
77. Bauman JL. Class III Antiarrhythmic Agents: The Next Wave. *Pharmacotherapy* 17:76S-

83S, 1997

78. Saseen JJ, Porter JA, Barnette DJ, Bauman JL, Zajac EJ, Carter BL. Evaluation of Post-Absorption Verapamil Concentration Peaks in Elderly Hypertensives. *Journal of Clinical Pharmacology* 37:526-534, 1997.
79. Gandhi AJ, Murphy CM, Zervopoulos PE, Evans RE, Carter BL, Bauman JL. Evaluation of Two Forms of Sustained Release Nifedipine Utilizing 24-Hour Ambulatory Blood Pressure Monitoring. *American Journal of Hypertension* 10:992-996, 1997.
80. Ghandi A, Vlases PH, Morton D, Bauman JL. Economic Impact of Digoxin Toxicity. *Pharmacoeconomics* 12:175-181, 1997.
81. Phillips BG, Gandhi AJ, Sanoski CA, Just VL, Bauman JL. Comparison of Intravenous Diltiazem and Verapamil for the Treatment of Acute Atrial Fibrillation and Atrial Flutter. *Pharmacotherapy* 17:1238-1245, 1997.
82. Bauman JL, Sanoski CA, Chan LN. Pharmacokinetic and Pharmacodynamic Drug Interactions with Antiarrhythmic Agents. *Cardiology in Review* 5:292-304, 1997.
83. Thomas AR, Chan LN, Bauman JL, Olopade CO. Drug Interaction with Diltiazem and Cisipride Resulting in QT Prolongation and Syncope. *Pharmacotherapy* 18:381-385, 1998.
84. DiDomenico RJ, Seeger J, Chami Y, Bauman JL. Worsening Angina Pectoris Associated with Phentermine in a Patient with Coronary Artery Disease. *Journal of Applied Therapeutic Research* 2:63-67, 1998.
85. Sanoski C, Schoen MD, Gonzalez RC, Avital B, Bauman JL. Rationale, Development and Outcomes of a Multidisciplinary Clinic for Patients Receiving Chronic Oral Amiodarone. *Pharmacotherapy* 18:146S-151S, 1998.
86. Gandhi, AJ, Bauman JL: Effect of Thioridazine on QT dispersion. *Journal of Applied Therapeutic Research* 2:109-114, 1999.
87. Southworth MR, Viana M, Bauman JL. A Comparison of Quinidine and Sotalol for the Maintenance of Normal Sinus Rhythm in Patients with Chronic Atrial Fibrillation *American Journal of Cardiology* 1999;83:1629-1632.
88. Brecklin CS, Bauman JL. Cardiovascular Effects of Cocaine: Focus on Hypertension. *Journal of Clinical Hypertension* 26:212-217, 1999.
89. DiDomenico R, Sanoski CA, Walton SM, Bauman JL. Analysis of the Use of Digoxin Immune Fab for the Treatment of Non-Life-Threatening Digoxin Toxicity. *Journal of Cardiovascular Pharmacology and Therapeutics* 5:77-85, 2000.
90. Haverkamp W, Breithardt G,..... Bauman JL, et al. The Potential for QT Prolongation and Proarrhythmia by Non-antiarrhythmic Drugs. Clinical and Regulatory Implications.

Report on a Policy Conference of the European Society of Cardiology. *European Heart Journal* 21:1216-1231, 2000 and *Cardiovascular Research* 47:219-233, 2000.

91. Hilleman DE, Bauman JL. The Role of Antiarrhythmic Therapy in Patients at Risk of Sudden Death: An Evidence-Based Review. *Pharmacotherapy* 21:556-575, 2001.
92. Bauman JL. The Role of Pharmacokinetics, Drug Interactions and Pharmacogenetics in the Acquired Long QT Syndrome. *European Heart Journal* 3:K93-K100, 2001.
93. Schoen MDS, DiDomenico R, Connor S, Dischler J, Bauman JL. The Impact of the Cost of Prescription Drugs on Outcomes in Indigent Patients with Cardiovascular Disease. *Pharmacotherapy* 21:1455-1463,2001.
94. Sanoski CA, Bauman JL. Clinical Observations with the Amiodarone - Warfarin Interaction: Dosing Relationships with Chronic Therapy. *Chest* 121:10-23, 2002.
95. Fong HHS, Bauman JL. Hawthorn in Cardiovascular Disease. *Journal of Cardiovascular Nursing* 16:1-8, 2002.
96. Bauman JL, DiDomenico RJ. Cocaine-induced Channelopathies: Emerging Evidence on the Multiple Mechanisms of Sudden Death. *Journal of Cardiovascular Pharmacology and Therapeutics* 7:195-202, 2002.
97. Schumock GT, Butler MG, Vermeulen LC, Meek PD, Arondeker BV, Bauman JL. Evidence of the Economic Benefit of Clinical Pharmacy Services:1996-2000. *Pharmacotherapy* 23:113-132, 2003.
98. Bauman JL. Tales of Two Oral Anticoagulants from Natural Sources and Their Impact on Clinical Pharmacy. *Pharmacotherapy* 24:166s-168s, 2004.
99. Bauman JL, Talbert RL. Pharmacodynamics of Beta-Blockers in the Treatment of Heart Failure: Lessons From COMET. *Journal of Cardiovascular Pharmacology and Therapeutics* 9:117-128, 2004.
100. Nutescu EA, Bauman JL. Shifting Paradigms in Oral Anticoagulation Management. *Journal of Cardiovascular Pharmacology and Therapeutics* 9:149-150, 2004.
101. Bauman JL, DiDomenico RJ, Galanter WL. Mechanisms, Manifestations and Management of Digoxin Toxicity in the Modern Era. *American Journal of Cardiovascular Drugs* 6:77-86, 2006.
102. Bauman JL, DiDomenico RJ, Viana M, Fitch M. A Method of Determining the Dose of Digoxin for Heart Failure in the Modern Era. *Archives of Internal Medicine* 166:2539-2545, 2006.
103. Myktysey A, Bauman JL, Akbar T, Razminia M, Zheutlin T, Wang T, Saleem M, Leal S, Kehoe RF. Observations on the Safety and Effectiveness of Dofetilide in Patients with Paroxysmal Atrial Fibrillation and Normal Left Ventricular Function. *Journal of*

*Cardiovascular Pharmacology and Therapeutics* 12:36-43, 2007.

104. Bauman JL, Evans WE. PharmD-Only Investigators are Critical for the Profession: Let's Preserve the Fellowship as an Equally Important Way to Prepare Future Clinical Pharmaceutical Scientists. *Pharmacotherapy* 29:129-133, 2009.
105. Awe C, Bauman JL. A Theoretical and Conceptual Framework of a College of Pharmacy High School Pathways to Pharmacy Program. *American Journal of Pharmaceutical Education* 74:1-11,2010.
106. Stubbins JA, Nutescu E, Durley SF, Bauman JL. Payment for Clinical Pharmacy Services Revisited. *Pharmacotherapy* 31: 1-8, 2011.
107. Svensson CK, Speedie MK, Roberts JC, LeTendre DE, Bruggemeier RW, Bauman JL, Ascione FJ. Reconsidering the Length of Program Accreditation. *American Journal of Pharmaceutical Education* 75:1-2, 2011

---

## ABSTRACTS

---

1. Maddux M, Organek H, Hasegawa G, Leeds N, Bauman JL: Erythromycin Alteration of Theophylline Pharmacokinetics: Lack of Effect at Steady State. *American Review of Respiratory Diseases* 123:60 1981.
2. Bauman JL, Bauernfeind RA, Hoff JV, Pietras R, Rosen KM: Quinidine Related Torsade de Pointes - 29 Cases. *Clinical Research* 29:690A, 1981.
3. Bauman JL, Bauernfeind R, Swiryn S, Strasberg B, Palileo E, Hoff JV, Rosen KM: Safety and Efficacy of Long-term Disopyramide Phosphate. *American Journal of Cardiology* 19:1003,1982.
4. Bauman JL, Bauernfeind R, Hoff JV, Rosen KM: Quinidine Syncope: Observations in 31 Patients. *Drug Intelligence and Clinical Pharmacy* 16:469, 1982.
5. Bauman JL, Strasberg B, Prechel D, Coehlo A, Bauernfeind RA: Long-term Safety and Efficacy of Aprindine. *Clinical Research* 30:704A, 1982.
6. Bauman JL, Strasberg B, Coehlo A, Prechel D, Bauernfeind RA: Long-term Safety and Efficacy of Aprindine. *Drug Intelligence and Clinical Pharmacy* 17:435, 1983.
7. Shanes JG, Kondos GT, Cooper R, Wolfkiel C, Juska J, Bauman JL: Acute Hemodynamic effects of Pindolol versus Propranolol in Patients with Cardiomyopathies. *Clinical Research* 33:227A, 1985.
8. Witte KW, Zeller FP, Hatoum HT, Klamerus KJ, Bauman JL: Justification of Clinical Pharmacy Services on Cardiology Units. *Drug Intelligence and Clinical Pharmacy* 19:452, 1985.

9. Barbarash RA, Bauman JL, Srebro J, Lukazewski A, Rich S: Continuous Verapamil Infusions in the Treatment of Atrial Tachyarrhythmias. *Drug Intelligence and Clinical Pharmacy* 19:446, 1985.
10. Miller SM, Martinez JJ, Deal BJ, Bauman JL, Scagliotti D, Gallastegui JL: Electrophysiologic Testing of Tocainide and Mexiletine for Ventricular Tachycardia: Assessment of the Need to Test Both Drugs. *Clinical Research* 33:813A, 1985.
11. Maddux MS, Schrader BJ, Veremis SA, Mozes MF, Maturen A, Bauman JL: Digoxin-like Immunoreactive Substance (DLIS) in Renal Transplant Patients. *Drug Intelligence and Clinical Pharmacy* 20:466, 1986.
12. Berk SI, Gal P, Douglas JB, Bauman JL, McCue JD, Powell JR: The Effect of Oral Cimetidine on Total and Unbound Serum Lidocaine Concentrations in Patients with Suspected Myocardial Infarction: A Reevaluation. *Drug Intelligence and Clinical Pharmacy* 20:467, 1986.
13. Bauman JL, Gallastegui J, Prechel D, Anderson JL: Bethanedine Sulfate in Inducible Paroxysmal Ventricular Tachycardia. *Drug Intelligence and Clinical Pharmacy* 20:45, 1986.
14. Hariman RJ, Deal BJ, Gallastegui J, Hu D, Bauman JL: Are There Separate Right Atrial Islands Controlling the Heart Rhythm? *Circulation* 74:II-350, 1986.
15. Deal BJ, Scagliotti D, Gallastegui J, Bauman JL, Hariman RJ: Is the Antegrade Refractory Period Of The Kent Bundle Useful In Predicting Drug Response in Young Patients With Wolff-Parkinson-White Syndrome? *Circulation* 74:II-119, 1986.
16. Berk SI, Bauman JL, Gallastegui JL, Hariman RJ: Therapy with Amiodarone for Sustained Ventricular Tachycardia: Efficacy, Safety and Factors Influencing Long-term Outcome. *Drug Intelligence and Clinical Pharmacy* 21:6A, 1987.
17. Barbarash RA, Bauman JL, Fischer JH, Kondos GT, Batenhorst RL: Effect of Enzyme Induction on Verapamil Pharmacokinetics: The Verapamil-Rifampin Interaction. *Drug Intelligence and Clinical Pharmacy* 21:11A, 1987.
18. Barbarash RA, Bauman JL, Fischer JH, Kondos GT, Batenhorst RL: Near Total Reduction in Verapamil Bioavailability by Rifampin: Electrocardiographic Correlates. *Journal of the American College of Cardiology* 11:205A, 1988.
19. Bauman JL, Berry NS, Gallastegui JL, Beckman KJ, Hariman RJ: Analysis of Antiarrhythmic Drug Levels During Electrophysiologic Drug Testing. *Journal of the American College of Cardiology* 11:228A, 1988.
20. Beckman KJ, Gallastegui JL, Bauman JL, Hariman RJ: Can EPS Predict Subsequent Arrhythmic Events in WPW Patients with Infrequent or No Arrhythmias? *Journal of the American College of Cardiology* 11:79A, 1988.

21. Pieper JA, Barbarash RA, Johnson KE, Bauman JL: Rifampin Alters Serum Albumin Concentrations and Verapamil Protein Binding. *Clinical Pharmacology and Therapeutics* 43:146, 1988.
22. Hariman RJ, Gallastegui JL, Hu D, Beckman KJ, Bauman JL: High Incidence of Remission in Patients with Incessant Ventricular Tachycardia Discontinued from Antiarrhythmic Drugs. *Journal of the American College of Cardiology* 13:33A, 1989.
23. Berk SI, Beckman K, Hoon T, Hariman RI, Bauman JL: Pharmacokinetics and Pharmacodynamics of Sublingual Verapamil. *Pharmacotherapy* 9:177, 1989.
24. McCollam P, Bauman JL: Target Serum Concentrations: A Simple Method of Monitoring Antiarrhythmic Drugs During Acute and Chronic Therapy. *Pharmacotherapy* 9:176, 1989.
25. Just V, Schrader B, Paloucek F, Hoon T, Leiken J, Bauman JL: Evaluation of Drug Therapy for the Treatment of Hypertensive Urgencies in the Emergency Room. *Pharmacotherapy* 9:176, 1990.
26. Berry N, Bauman JL, Kasuya A, Paloucek F, Lerken J, Hutchinson RA: Evaluation of 24 hr Clinical Pharmacy Services with Emergency Room. *Pharmacotherapy* 9:181, 1989.
27. Parker R, Beckman K, Hariman RI, Bauman JL: The Electrophysiologic and Antiarrhythmic Effects of Cocaine. *Pharmacotherapy* 9:176, 1989.
28. Parker R, Beckman KJ, Bauman JL, Hariman RI: Sodium Bicarbonate Reverses Cocaine-Induced Conduction Defects. *Circulation* 78:26A, 1989.
29. Schoen MD, Hoon T, Parker R, Beckman KJ, Hariman RI, Bauman JL: Clarification of the Interaction Between IV Calcium Chloride and IV Verapamil. *Pharmacotherapy* 10:244, 1990.
30. Maddux MS, Schrader BJ, Veremis SA, Moses MF, Maturen A, Bauman JL: Digoxin-like Immunoreactive Substance (DLIS) in Renal Allograft Recipients. *Proceedings of the International Congress on Therapeutic Drug Monitoring* 1:212-215, 1990.
31. LaBreche DL, Kondos GT, Bartels DW, Vallejo-Sinavsky VL, Bauman JL: Comparative Effects of Diltiazem and Propranolol Upon Plasma Lipoproteins. *Pharmacotherapy* 10:247, 1990.
32. Hoon TJ, McCollam PL, Beckman KJ, Hariman RJ, Bauman JL: The Effects of Food Upon the Pharmacokinetics and Pharmacodynamics of Sustained-released Verapamil. *Pharmacotherapy* 11:100, 1991.
33. Tworek DA, Schoen MD, Fischer JH, Bauman JL: Bioavailability of Total and Unbound Disopyramide: Implications for the Conversion of the Immediate to the Controlled Release Dosage Form. *Pharmacotherapy* 12:251, 1992.
34. Roberts SA, Viana M, Bauman JL: Invasive and Noninvasive Methods to Predict the

- Efficacy of Amiodarone: A Compilation of Clinical Observations Using Meta-Analysis. *Pharmacotherapy* 12:244, 1992.
35. Inbar S, Tworek D, Bauman JL, Nazari J. The Effect of Disopyramide on Heart Rate Variability. *Chest* 102:2125, 1992.
  36. O'Toole M, Roberts S, Bauman JL, Nazari J, Stamato N. Does Esmolol Predict the Long-term Response to Oral Beta Blockers in Patients With Vasovagal Syncope? *Chest* 102:2125, 1992.
  37. Winecoff AP, Hariman RJ, Grawe JJ, Wang Y, Bauman JL. Effects of Various Drugs in Reversing Cocaine-Induced Slowed Ventricular Conduction Using Isolated Perfused Guinea Pig Hearts. *Pharmacotherapy* 12:500, 1992.
  38. Wang Y, Hariman RJ, Grawe JJ, Winecoff AP, Louie EK, Hwang MH, Loeb MS, Scanlon P, Bauman JL. Reversal of Cocaine-Induced Sodium Channel Blockade by Lidocaine. *Journal of the American College of Cardiology* 21:22A, 1993.
  39. Winecoff AP, Hariman RJ, Grawe JJ, Wang Y, Scanlon P, Bauman JL. Lidocaine is as Potent as Sodium Bicarbonate in Reversing Cocaine-Induced Slowing of Ventricular Conduction. *Journal of the American College of Cardiology* 21:23A, 1993.
  40. Grawe JJ, Hariman RJ, Winecoff AP, Fischer JH, Bauman JL. Lidocaine Reverses Cocaine-Induced Slowed Ventricular Conduction by Competitive Binding. *Clinical Pharmacology and Therapeutics* 53:135, 1993.
  41. Oberg KC, Bauman JL. Incidence of QT Prolongation and Torsade de Pointes Due to Intravenous Erythromycin. *Pharmacotherapy* 13:674, 1994.
  42. Grawe JJ, Hariman RJ, Winecoff AP, Bauman JL. Contrasting Actions of Cocaine on Ventricular Conduction and Repolarization: Effects of Lidocaine. *Pharmacotherapy* 13:676, 1994.
  43. Oberg K, O'Toole MF, Gallastegui JL, Bauman JL. Observations in Patients with "Late" Proarrhythmia Due to Quinidine. *Clinical Pharmacology and Therapeutics* 55:155, 1994.
  44. Oberg KC, Just VL, Bauman JL, Papp MA: Reduced Bioavailability of Enalapril in Patients with Severe Heart Failure. *Journal of the American College of Cardiology* 26:381A, 1994.
  45. Phillips BG, Schoen MDS, Hoon T, Schrader BJ, Bauman JL, Rich S. Pharmacodynamics of Nifedipine in Patients with Primary Pulmonary Hypertension. *Journal of Investigative Medicine* 43:339A, 1995.
  46. Yim JM, Hoon TJ, Bittar N, Bauman JL, Brown EJ, Celestin C, Phillips BG, Vlasses PH. Angiotensin-Converting Enzyme Inhibitor Use in Survivors of Acute Myocardial Infarction. *Pharmacotherapy* 15:365, 1995.

47. Phillips BG, Yim JM, Brown EJ, Bittar N, Hoon TJ, Celestin C, Vlasses PH, Bauman JL. Pharmacologic Therapy of Acute Myocardial Infarction in United States Teaching Hospitals. *Pharmacotherapy* 15:367-368, 1995.
48. Phillips BG, Gandhi AJ, Just VL, Bauman JL. Comparison of Intravenous Diltiazem and Verapamil for the Acute Treatment of Atrial Fibrillation and Flutter. *Pharmacotherapy* 15:402, 1995.
49. Hariman RJ, Liu D, Loeb HS, McKiernan J, Scanlon PJ, Bauman JL. Competitive Binding Between Cocaine and Lidocaine. *Journal of the American College of Cardiology* 27:80A, 1996.
50. Phillips BG, Evans RR, Singh G, Bauman JL, Gulati A. Endothelin-1: Racial and Gender Differences in Healthy Volunteers. *Pharmacotherapy* 16:127, 1996.
51. Gandhi AJ, Vlasses PH, Morton DJ, Bauman JL. Economic Impact of Digoxin Toxicity. *Pharmacotherapy* 16:493, 1996.
52. Gandhi AJ, Murphy CM, Dalecki TM, Zervopoulos PC, Bauman JL. Evaluation of Two Forms of Sustained Release Nifedipine Utilizing 24 Hour Ambulatory Blood Pressure Monitoring. *Pharmacotherapy* 16:494, 1996.
53. Gandhi AJ, Evans RR, Bailey L, Dalecki TM, Zervopoulos PC, Bauman JL. Effect of Thioridazine on QT Dispersion. *Pharmacotherapy* 16:493-494, 1996.
54. Evans R, Altura BT, Genthner D, Rich S, Bauman JL. Altered ionized magnesium and calcium in patients with primary pulmonary hypertension. *Chest* 110:108S, 1996.
55. Southworth MR, Viana ML, Bauman JL. Does Sotalol Increase Mortality in Patients With Atrial Fibrillation? Comparison with Quinidine by Meta - Analysis. *Pharmacotherapy* 17:1082-1083, 1997.
56. Sanoski C, Schoen MDS, Gonzales R, Bauman JL. Improved Outcomes with an Interdisciplinary Specialized Clinic for Patients Receiving Amiodarone. *Pharmacotherapy* 17:1123-1124, 1997.
57. Schoen MDS, Dischler J, Connor S, Zervopoulos P, Kline C, Bauman JL. Economic Outcomes and Medication Compliance in a Prescription Procurement Clinic for Indigent Patients with Cardiovascular Disease. *Circulation* 96:I-617, 1997.
58. Sanoski C, Bauman JL. Long-term Characterization of the Amiodarone - Warfarin Drug Interaction. *Journal of the American College of Cardiology* 31:507A, 1998.
59. Sanoski CA, Vasquez, EM, Bauman JL. QT Interval Prolongation Associated with the Use of Tacrolimus in Transplant Recipients. *Pharmacotherapy* 18:427, 1998.
60. Sanoski CA, Takahashi H, Echizen H, Brace L, Helgason C, Schuler J, Bauman JL, Nutescu E. Effects of Age and Weight on the Pharmacokinetics of Warfarin.

*Pharmacotherapy* 18:427, 1998.

61. Sanoski CA, Takahashi H, Echizen J, Brace L, Helgason C, Schuler J, Bauman JL, Nutescu E. Effect of Gender on the Pharmacokinetics of Warfarin. *Pharmacotherapy* 18:427, 1998.
62. DiDomenico RJ, Sanoski CA, Walton SM, Bauman JL. Cost-Effectiveness Analysis of the Use of Digoxin Immune Fab for the Treatment of Non-Life Threatening Digoxin Toxicity. *Pharmacotherapy* 18:427, 1998.
63. Sanoski CA, Takahashi H, Echizen H, Brace L, Helagason C, Schuler J, Bauman JL, Nutescu E. Effect of Cigarette Smoking on the Pharmacokinetics of Warfarin. *Pharmacotherapy* 18:1142-1143, 1998.
64. DiDomenico R, Schoen MD, Connor S, Bauman JL. The Effects of the Cost of Prescription Drugs on Clinical Outcomes in Patients with Cardiovascular Diseases. *Pharmacotherapy* 19:506, 1999.
65. DiDomenico R, Fain J, Bauman JL. Cost-Minimization Analysis of Elective Cardioversion Guided by Transesophageal Echocardiography Followed by Early Hospital Discharge for the Acute Management of Atrial Fibrillation. *Pharmacotherapy* 20:1260-1261, 2000.
66. Butler MG, Schumock GT, Meek PD, Vermeulen LC, Arendokar BV, Bauman JL. Economic Evaluation of Clinical Pharmacy Services, 1996-2000. *Pharmacotherapy* 22:1360, 2002
67. Beitelshes AL, Bauman JL, Southworth MR, Didomenico RJ, Dunlap SH, Fashingbauer LA, Humma LM. Cost-savings Associated with a Decreased Need for Potassium Supplementation in Heart Failure Patients on Spironolactone. *Pharmacotherapy* 22:1326, 2002.
68. Tanzi MG, Schoen MD, Bauman JL. Clinical Experience with Ultra-low Dose Amiodarone (100mg/day). *Pharmacotherapy* 22:1327, 2002.
69. Blackburn J, Schumock G, Bauman JL, Nutescu E. Barriers to Appropriate Anticoagulation with Warfarin in Orthopedic Surgery. *Journal of Thrombosis and Haemostasis*. 3(Suppl 1):430, 2005.
69. Mykytsey A, Santos M, Zheutlin T, Wang T, Nazari J, Bauman JL, Kehoe R. Efficacy of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. *Heart Rhythm* 2:S191, 2005.
70. Pickard AS, Bauman JL. An Inquiry into the Research Interests and Support Needs of Clinical Pharmacy Faculty. at [http://www.pharmacotherapy.org/pdf/ACCP-Spring\\_Abstacts\\_2006.pdf](http://www.pharmacotherapy.org/pdf/ACCP-Spring_Abstacts_2006.pdf)
71. Fitch M, DiDomenico RJ, Viana M, Bauman JL. Methods for Dosing Digoxin in the Modern Era. at

[http://www.pharmacotherapy.org/pdf/ACCP-Spring\\_Abstracts\\_2006.pdf](http://www.pharmacotherapy.org/pdf/ACCP-Spring_Abstracts_2006.pdf)

72. DiDomenico RJ, Bauman JL, Viana M, Fitch M. A New and Simple Dosing Algorithm for Digoxin in Patients with Heart Failure. *Journal of Cardiac Failure* 12:S85,2006.
73. Nutescu EA, Bautista A, Weihua G, Stamos T, Galanter W, Garofalo J, Bauman JL. Quality of Oral Anticoagulation Management in Pharmacist vs Nurse Managed Models of Care. *Blood* 112:A4665, 2008.
74. DiDomenico RJ, Schumann HS, Bauman JL. Digoxin Toxicity in the Modern Era. *Clinical Toxicology* 46:368, 2008.
75. DiDomenico RJ, Na-Thalang K, Tsao Y, Groo VL, Bishop JR, Viana MAG, Bauman JL. Use of a Simplified Nomogram to Individualize Digoxin Dosing in Heart Failure Patients vs. Standard Care. *Pharmacotherapy* 30:376e, 2010.

---

#### **PUBLICATIONS - BOOK CHAPTERS**

---

1. Bauman JL: "Cardiac Drugs" in *Handbook of Clinical Drug Data* 5th Edition, Knoben JE, Anderson PO, Troutman WG (Eds), Drug Intelligence Publications Inc., Hamilton, Illinois pp 410-426, 1983.  
  
6th Edition, pp 469-496, 1988.  
7th Edition, pp 568-582, 1993.  
8th Edition, pp 227-317, 1996.  
9th Edition, pp 288-312 & 347-387, 1999.  
10th Edition pp 297-323 & 354-367, 2002
2. Bauman JL, Gallastegui J: "Diagnosis and Treatment of Paroxysmal Supraventricular Tachycardia" in *Cardiovascular Emergencies*, Ornato JP (Ed), Churchill Livingstone Inc., New York, New York pp 77-96, 1986.
3. Bauman JL: "Mexiletine" in *A Textbook for the Clinical Application of Therapeutic Drug Monitoring*. Taylor W (Ed), Abbott Diagnostics, Irving, Texas pp 125-131, 1986.
4. Bauman JL: "Monitoring of Drug Therapy" in *Great Lakes Regional Conference on Clinical Pharmacy Practice*. Posey M (Ed), Illinois Council of Hospital Pharmacists, Chicago, Illinois, 1987.
5. Bauman JL, Sanoski C, Schoen MD: "The Arrhythmias" in *Pharmacotherapy: A Pathophysiologic Approach* 1st Edition. DiPiro J, Talbert R, Yee G, Matzke G, Wells B, and Posey M (Eds), McGraw Hill, New York, New York pp 150-172, 1988.  
  
2<sup>nd</sup> Edition, pp 255-283, 1992.

- 3<sup>rd</sup> Edition, pp 323-359, 1996.  
4<sup>th</sup> Edition, pp 232-264, 1999.  
5<sup>th</sup> Edition, pp 273-303, 2002.  
6<sup>th</sup> Edition, pp 321-356, 2005.  
7<sup>th</sup> Edition, pp 279-314, 2008.  
8<sup>th</sup> Edition pp 273-309, 2011.
6. Bauman JL, Parker R, McCollam P: "Tachycardias" in *Pharmacotherapy Self-assessment Program (PSAP)*, Carter BL, Sisca T, Angaran D, Host T (Eds), ACCP Publications, Kansas City, Missouri pp 101-122, 1992 (Cardiology Section chair).
- 2<sup>nd</sup> Edition, pp 207-234, 1995.
7. Bauman JL: "Vasodilating Agents" in *Handbook of Clinical Drug Data* 7th Edition, Knoben JE, Anderson PE, Troutman W (Eds), Drug Intelligence Publications, Hamilton, Illinois pp 568-582, 1993.
8. Southworth MR, Bauman JL: "Cardiology Clinical Pharmacy Practice" in *Encyclopedia of Clinical Pharmacy* DiPiro J (Ed), Marcel Dekker, Inc. New York, NY, pp 119-126, 2003.
9. Bauman JL, Fischer J, Takahashi H: "Clinical Pharmacokinetics of the Oral Antiarrhythmic Drugs" in *Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring* 4th Edition, Burton ME, Shaw LM, Schentag JJ, Evans WE, (Eds), Applied Therapeutics, Inc., Vancouver, WA pp 440-462, 2005.
10. Dahdal WY, Bauman JL: "Cardiovascular Disorders" in *Gibaldi's Drug Delivery Systems in Pharmaceutical Care*. Desai A, Lee M (Eds), American Society of Health-System Pharmacists, Bethesda, MD pp 197-231, 2007.

---

## MULTICENTER STUDIES

---

1. Teichman SL, et al and the participating members of the Multicenter Bethanedine Study. Bethanedine Sulfate: Efficacy in Prevention of Ventricular Tachyarrhythmias During Programmed Stimulation. A Report of a Multicenter Study of 56 Patients. *Journal of the American College of Cardiology* 6:510-517, 1985
2. Massey B, et al for The Diltiazem Versus Propranolol Multicenter Study Group. Diltiazem and Propranolol in Mild to Moderate Essential Hypertension as Monotherapy or With Hydrochlorothiazide. *Annals of Internal Medicine* 107:150-157, 1987.
3. Huycke EC et al for The Multicenter Diltiazem PSVT Investigators. Intravenous Diltiazem for Termination of Reentrant Supra-ventricular Tachycardia: A Placebo-Controlled, Randomized, Double-Blind, Multicenter Study. *Journal of the American College of Cardiology* 13:538-544, 1989.
4. Albers GW et al for The UHC Atrial Fibrillation Investigators. Status of Antithrombotic Therapy for Patients With Atrial Fibrillation in University Hospitals. *Archives of Internal*

*Medicine* 156:2311-2316, 1996.

5. The Digitalis Investigation Group. The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. *New England Journal of Medicine* 336:525-533, 1997.
6. Naccarelli GV et al for the Flecainide Multicenter Atrial Fibrillation Study Group. Prospective Comparison of Flecainide versus Quinidine for the Treatment of Paroxysmal Atrial Fibrillation/Flutter. *American Journal of Cardiology* 77:53A-59A, 1996
7. Albers GW et al for the UHC Atrial fibrillation Investigators. Clinical Characteristics and Management of Acute Stroke in Atrial Fibrillation Patients Admitted to University Hospitals. *Neurology* 48:1598-1604, 1997.

---

#### **PUBLICATIONS - MISCELLANEOUS**

---

1. Bauman JL, Siepler JK: Intravenous Phenytoin (concluded) *New England Journal of Medicine* 296: 111, 1976. (letter).
2. Bauman JL, Siepler JK: Phenytoin Crystallization in Intravenous Fluids. *American Journal of Hospital Pharmacy* 35:20-21, 1978. (letter).
3. Bauman JL, Curtis, RA: New Concepts in Arrhythmogenesis and Antiarrhythmic Mode of Action. *Voices - 79* (tape) 9(5), 1979.
4. Bauman JL, Curtis RA, Covinsky JO: Effects of Antiarrhythmics in Ischemic Models. *American Heart Journal* 100:947-948, 1980. (letter).
5. Maddux M, Bauman JL: The Theophylline-Erythromycin Interaction. *Chest* 84:311-312, 1983. (letter reply).
6. Bauman JL: Evaluation of Indapamide-Commentary. *Pharmacotherapy*
7. Bauman JL, Gearien JE: Book review: "Receptor Science in Cardiology." *Chest* 87:22, 1985.
8. Bauman JL: Book review: "Cardiovascular Drugs and the Management of Heart Disease." *Chest* 87:59, 1985.
9. Schrader B, Bauman JL: Mexiletine-Commentary. *Pharmacotherapy* 6:7-8, 1986.
10. Kendzierski D, Bauman JL: Book review: "Respiratory Pharmacology and Toxicology." *Chest* 89:22, 1986.
11. Bauman JL: Book review: "Lecture Notes on Pharmacology". *Critical Care Medicine*

- 15:185, 1987.
12. Berk SI, Bauman JL: Enalapril-Commentary. *Pharmacotherapy* 7:145-146, 1987.
  14. Berry NS, Bauman JL: Lovastatin-Commentary. *Pharmacotherapy* 7:210, 1987.
  15. Bauman JL, et al: Treatment of Post-MI Arrhythmias. *Therapeutic Trends* pp 6-8 1988. (newsletter and videotape).
  16. Bauman JL: Roundtable on Thrombolytic Therapy. *U.S. Pharmacist* 13:H31-H44, 1988.
  17. Bauman JL, Hariman RI: Book Review: "Cardiovascular Pharmacology 87". *Chest* 94: 18-19, 1988.
  18. Bauman JL: Pathophysiology of Reentrant SVT. *Treatment and Controversies* pp 2-8, 1989. (newsletter).
  19. Bauman JL: Pharmacokinetic Research: Tips for Clinicians. In *Proceedings from Focus on Illinois Clinicians*. pp 81-84, 1989.
  20. Bauman JL: Counseling Patients Receiving Type Ia Antiarrhythmic Agents. *Consultation in Pharmacy Practice* August 1993. (newsletter).
  21. Bauman JL: One Minute Counsellor: Ventricular Arrhythmias Part 1. *ACCP Report* 14:3-4, 1995.
  22. Bauman JL. One Minute Counsellor: Ventricular Arrhythmias Part 2. *ACCP Report* 14:7-8, 1995.
  23. Bauman JL. Book review: "Therapeutic Drug Monitoring". *Doody's Journal* 3:266, 1995
  24. Bauman JL. The ACCP Scientific Series: Trends and Thoughts. *ACCP Report* 16:2-3, 1997.
  25. Bauman JL. ACCP. A Scientific Society Filled with Practitioners. *ACCP Report* 16:3,
  26. Bauman JL. PRNs or PSGs (Potential Splinter Groups)? *ACCP Report* 16:2, 1997.
  27. Bauman JL. That Darn Membership Form. *ACCP Report* 17:2, 1998.
  28. Bauman JL. I Get Letters. *ACCP Report* 17:2, 1998.
  29. Bauman JL. You Talkin' to Me? *ACCP Report* 17:2, 1998.
  30. Bauman JL. Random Notes. *ACCP Report* 17:2, 1998.
  31. Bauman JL. Murphy JE, Bertino JS. Pharmacists and Infectious Diseases Specialists. *Clinical Infectious Diseases* 27: 229, 1998 (letter).

32. New Product Bulletin: Cardiazem®. Bauman JL (Editor) *APhA CE Monograph*: American Pharmaceutical Association, 1998.
33. Bauman JL. Amiodarone. From Last to First-Line Antiarrhythmic Therapy. Editor, CE Monograph: Cortex Communications/Wyeth Ayerst, 1999.
34. Bristow MR, Adams KF, Bauman JL, Feldman AM, Giles TD, Goldstein S, Mann DL, Talbert RL. Roundtable Discussion: The COMET Trial. *Congestive Heart Failure* 11:39-44, 2005
35. Pharmacological Interventions in Atrial Fibrillation: A Focus on Rhythm Control Strategies. CE Monograph Bauman JL (Editor). BiMark Medical Communications, 2005.
36. Bauman JL. Response to Cardiovascular Toxicity. *Southern Medical Journal* 99:781,2006 (letter).

---

## **INTELLECTUAL PROPERTY**

---

1. Nanodarone™. Amiodarone dispersed in hydrophilic micelles for intravenous use (with Hayat Onyuksel, PhD).
2. Digoxin dosing application for Android and iPhone/iPad devices (with Robert Didomenico, PharmD and Sean Kane, PharmD).  
<http://iphoneapplicationlist.com/app/id483020061/>  
[https://market.android.com/details?id=com.clincalc.digoxin&feature=search\\_result#?t=W251bGwsMSwyLDEsImNvbS5jbGluY2FsYy5kaWdveGluIllo](https://market.android.com/details?id=com.clincalc.digoxin&feature=search_result#?t=W251bGwsMSwyLDEsImNvbS5jbGluY2FsYy5kaWdveGluIllo).

---

## **EDITORIAL BOARDS**

---

*Pharmacotherapy*, 1991 – present  
Scientific Editor, 2006 – present

*ISRN Pharmacology*, 2010 - present

*Journal of Applied Therapeutic Research*, 1993 – present  
Editor – USA

*Evaluations of Drug Interactions*, 1986 - present

*Journal of Cardiovascular Pharmacology and Therapeutics*, 1999 - 2007

*Phytomedicine*, 1996 - 2006

*Journal of Cardiovascular Nursing*, 1997 - 2009

*P & T Journal*, 1985 - 1993

*American Journal of Health System Pharmacists*, 1994 - 1998

*ACCP Report* (Editor), 1985 - 1987

*Hospital Physician*, 1984 - 1991

*DrugDex* (Micromedix), 1988 - 1999

*Clinical Pharmacy*, 1989 - 1994

*Drug Intelligence and Clinical Pharmacy* (Cardiology Panel),  
1984 - 1987

*Applied Pharmacokinetics*, 3rd Edition 1992

Reviewer Services: *Archives of Internal Medicine, Chest, American Journal of Cardiology, Circulation, American Heart Journal, PharmacoEconomics, Heart, The Medical Letter, British Journal of Clinical Pharmacology, Southern Medical Journal, Clinical Pharmacology and Therapeutics*

---

## **OTHER APPOINTMENTS**

---

**Delegate, United States Pharmacopeia**  
2010-2015

**Member, ASHP Commission on Credentialing**  
National Pharmacy Residency Accreditation, 2005 - 2008

**Member, Steering Committee**  
University of Illinois at Chicago DEcIDE center, U.S. Department of Health and Human Services Agency for Healthcare Research and Quality, 2005 - 2010

**Member, State of Illinois Drugs and Therapeutics (formulary) Committee**  
Consultant to Illinois State Medical Society and Illinois Department of Public Aid, 1982 - 2004

**Member, U.S. Pharmacopeia Cardio-Renal Advisory Panel**  
U.S. Pharmacopeia Convention, Inc., 1995 - 2000

**Member, Cardiovascular Panel, Study of Clinically Relevant Indicators for Pharmacologic Therapy (SCRIPT)**  
Joint Commission on Accreditation of Healthcare Organizations, 1999 - 2000

**Board of Pharmaceutical Specialties Nutrition Council** (non-specialty member), 2002 - 2004

**Scientific Advisory Committee, University of Illinois General Clinical Research Center** (NIH MO1-RR-13987), 1997 - 2005

**Consultant in Pharmacology**

Section of Cardiology  
Hines VA Hospital, 1990 - 1995

**Consultant in Pharmacology**

Section of Cardiology  
Jesse Brown West Side VA Hospital, 1981 - 1990

**Subcommittee Member, Committee on Clinical Pharmacy as a Specialty**, 1981 - 1985  
(Preparation of petition on Clinical Pharmacy - then Pharmacotherapy - to the Board of Pharmaceutical Specialties)

---

**PROFESSIONAL AFFILIATIONS**

---

**American College of Clinical Pharmacy**

Fellow (elected) 1991 - present  
Secretary 1985 - 1987  
Board of Regents 1987 - 1990  
President - elect 1996 - 1997  
President 1997 - 1998  
Chair, Research Institute Board of Trustees 1998 - 1999

**American College of Cardiology**

Fellow (elected) 1993 - present  
Associate Fellow 1983 - 1993

**American Association of Colleges of Pharmacy**

**Cardiac Electrophysiology Society**

**American Heart Association**

**American Society of Health System Pharmacists**

Select invited national and international presentations, grant support, national committees and references – available upon request

01/12